EUVIMEDOpdag EUVIMED
Open access

Mucoadhesive tumor-penetrating nanomedicine for intravesical chemo-immunotherapy against bladder cancer

Changhao Zhao iD, Dayong Hou iD, Kaiwei Wang, Jianjiang Chen, Yumin Wu, Nanhui Liu, Zhen Wang, Yanbin Liu iD, Yaowei Li, Zhishuai Zhang, Yi Liu iD, Zhuyu Hou and 6 more

Science Advances · 2026-04-17 · 12 (16)

DOI: 10.1126/sciadv.aeb9764 ↗

At a glance

Journal article in Science Advances, published on 2026-04-17. Written by Changhao Zhao and 17 co-authors. Institution: Department of Urology, Harbin Medical University Cancer Hospital, NHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical Uni…. Major MEDLINE topics: Immunotherapy, Urinary Bladder Neoplasms, Nanomedicine. Cited 4 times so far (Crossref); 54 references. The full text is freely available in PubMed Central. Funded by: Key Research and Development Program of Heilongjiang, National Natural Science Foundation of China, Heilongjiang Provincial Natural Science Foundation of China.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Intravesical administrations of chemotherapeutics or immune-agonist Bacillus Calmette-Guérin (BCG) are first-line treatments for non–muscle-invasive bladder cancer (NMIBC). However, while urination prevents drug retention in the bladder, the bladder mucus, epithelial barrier, and dense tumor stroma form multiple physical barriers that restrict intratumoral drug penetration. Here, we developed thiol-functionalized bacterial membrane–coated nanoparticles loaded with a chemotherapeutic agent epirubicin (EPI) for highly effective intravesical chemo-immunotherapy against bladder tumors. The surface thiol groups enabled urine-resistant adhesion to the mucin-rich bladder mucosa through dynamic disulfide bonds, as demonstrated in both mouse and human bladders. Meanwhile, we unexpectedly found that bacterial membrane components up-regulated matrix metalloproteinases (MMPs), facilitating tight junction disruption and collagen degradation, thereby enhancing nanoparticle penetration into tumors. Intratumoral delivery of EPI by such nanomedicine would induce robust immunogenic cell death (ICD), which by synergizing with the immunoadjuvant properties of the bacterial membrane can elicit tumor-specific immune responses, resulting in potent antitumor efficacy in both NMIBC and muscle-invasive bladder cancer (MIBC) mouse models. Notably, combination with immune checkpoint blockade further amplified systemic antitumor immunity, leading to complete regression of orthotopic bladder tumors and marked inhibition of distant lesions. Our unique nanomedicine platform by addressing challenges in current intravesical therapies would be highly promising for potent intravesical chemo-immunotherapy of bladder malignancies.

Subjects

MeSH terms (MEDLINE)

ImmunotherapyUrinary Bladder NeoplasmsNanomedicineAnimalsHumansMiceAdministration, IntravesicalNanoparticlesNon-Muscle Invasive Bladder NeoplasmsCell Line, TumorFemaleMucous Membrane

Authors and institutions

  • Department of Urology, Harbin Medical University Cancer Hospital, NHC Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University, Harbin 150001, China.
  • Institute of Functional Nano and Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou 215123, China.
  • College of Pharmaceutical Science, Soochow University, Suzhou 215123, China.
  • Biomedical Basic Research Center (BBRC) of Jiangsu Province, Suzhou, 215123, China.

ORCID profiles: Changhao Zhao, Dayong Hou, Yanbin Liu, Yi Liu, Wanhai Xu, Ziqi Wang, Han Zhang, Zhuang Liu

Funding

  • Key Research and Development Program of Heilongjiang
  • National Natural Science Foundation of China
  • Heilongjiang Provincial Natural Science Foundation of China
  • Fundo para o Desenvolvimento das Ciências e da Tecnologia
  • The National Center of Technology Innovation for Biopharmaceuticals
  • Jiangsu Key R&D Program (Social Development) Project
  • Collaborative Innovation Center of Suzhou Nano Science and Technology, and the 111 Program from the Ministry of Education of China
  • New Cornerstone Science Foundation

Cite

APA

Zhao, C., Hou, D., Wang, K., Chen, J., Wu, Y., Liu, N., Wang, Z., Liu, Y., Li, Y., Zhang, Z., Liu, Y., Hou, Z., Yang, X., Liu, X., Xu, W., Wang, Z., Zhang, H., & Liu, Z. (2026). Mucoadhesive tumor-penetrating nanomedicine for intravesical chemo-immunotherapy against bladder cancer. Science Advances, 12(16). https://doi.org/10.1126/sciadv.aeb9764

Vancouver

Zhao C, Hou D, Wang K, Chen J, Wu Y, Liu N, et al. Mucoadhesive tumor-penetrating nanomedicine for intravesical chemo-immunotherapy against bladder cancer. Science Advances. 2026;12(16). doi:10.1126/sciadv.aeb9764

BibTeX
@article{Zhao2026,
  author = {Zhao, Changhao and Hou, Dayong and Wang, Kaiwei and Chen, Jianjiang and Wu, Yumin and Liu, Nanhui and Wang, Zhen and Liu, Yanbin and Li, Yaowei and Zhang, Zhishuai and Liu, Yi and Hou, Zhuyu and Yang, Xiaodan and Liu, Xiao and Xu, Wanhai and Wang, Ziqi and Zhang, Han and Liu, Zhuang},
  title = {Mucoadhesive tumor-penetrating nanomedicine for intravesical chemo-immunotherapy against bladder cancer},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {16},
  doi = {10.1126/sciadv.aeb9764}
}
Start for free →